Literature DB >> 6224808

B-scan ultrasonic evaluation of a dilated superior ophthalmic vein in orbital and retro-orbital arteriovenous anomalies.

M R Moster, J S Kennerdell.   

Abstract

All patients between 1977 and 1982 who presented with unilateral exophthalmos were evaluated with contact B-scan ultrasonography. Of these, eight patients were diagnosed as having retro-orbital or orbital arteriovenous anomalies (two carotidcavernous sinus fistulas, four dural arteriovenous malformations, and two orbital arteriovenous malformations). On B-scan ultrasound, all of these patients demonstrated a dilated superior ophthalmic vein. None of the other patients with unilateral proptosis demonstrated this finding. With recent advances in treatment of these conditions, early diagnosis becomes increasingly important. Contact B-scan ultrasonography (which is widely available, convenient, and expedient) can be used for early diagnosis of arteriovenous anomalies in the orbit and cavernous sinus areas. Other ultrasonic techniques such as A-scan, standardized A-scan, or immersion B-scan, are equally reliable in the recognition of a dilated superior orbital vein. In the authors' opinion, however, these are less convenient, more time consuming, and require more expertise for similar results.

Entities:  

Mesh:

Year:  1983        PMID: 6224808

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  3 in total

Review 1.  Cavernous sinus fistulas: carotid cavernous fistulas and dural arteriovenous malformations.

Authors:  Leonard Feiner; Jeffrey Bennett; Nicholas J Volpe
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

2.  Intraorbital arteriovenous malformation: case report.

Authors:  J L Gil-Salú; J M González-Darder; J M Vera-Román
Journal:  Skull Base       Date:  2004-02

3.  Colour Doppler imaging in the demonstration of an orbital varix.

Authors:  W E Lieb; D A Merton; J A Shields; S M Cohen; D D Mitchell; B B Goldberg
Journal:  Br J Ophthalmol       Date:  1990-05       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.